All Stories

  1. XBP1 et réponse inflammatoire des macrophages alvéolaires au cours de la mucoviscidose

    Article • médecine/sciences, April 2017, EDP Sciences

    Dr Bob A. Lubamba

  2. X-Box–Binding Protein 1 and Innate Immune Responses of Human Cystic Fibrosis Alveolar Macrophages

    Article • American Review of Respiratory Disease, December 2015, American Thoracic Society

    Dr Bob A. Lubamba

  3. Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy

    Article • Clinical Biochemistry, October 2012, Elsevier

    Dr Bob A. Lubamba

  4. Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice

    Article • Journal of Cystic Fibrosis, July 2012, Elsevier

    Dr Bob A. Lubamba

  5. Pharmacological Potential of PDE5 Inhibitors for the Treatment of Cystic Fibrosis

    Article • March 2012, IntechOpen

    Dr Bob A. Lubamba

  6. Comparative Variability of Nasal Potential Difference Measurements in Human and Mice

    Article • Open Journal of Respiratory Diseases, January 2012, Scientific Research Publishing, Inc,

    Dr Bob A. Lubamba

  7. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice

    Article • European Respiratory Journal, June 2010, European Respiratory Society (ERS)

    Dr Bob A. Lubamba

  8. Airway Delivery of Low-Dose Miglustat Normalizes Nasal Potential Difference in F508del Cystic Fibrosis Mice

    Article • American Review of Respiratory Disease, June 2009, American Thoracic Society

    Dr Bob A. Lubamba

  9. Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis

    Article • American Review of Respiratory Disease, March 2008, American Thoracic Society

    Dr Bob A. Lubamba